NUVL
Price
$90.12
Change
-$1.23 (-1.35%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
7.35B
64 days until earnings call
Intraday BUY SELL Signals
OLMA
Price
$10.48
Change
-$0.21 (-1.96%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
933.74M
69 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NUVL vs OLMA

Header iconNUVL vs OLMA Comparison
Open Charts NUVL vs OLMABanner chart's image
NUVL vs OLMA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
NUVL vs. OLMA commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a StrongBuy and OLMA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 03, 2026
Stock price -- (NUVL: $91.35 vs. OLMA: $10.69)
Brand notoriety: NUVL and OLMA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 255% vs. OLMA: 261%
Market capitalization -- NUVL: $7.35B vs. OLMA: $933.74M
NUVL [@Biotechnology] is valued at $7.35B. OLMA’s [@Biotechnology] market capitalization is $933.74M. The market cap for tickers in the [@Biotechnology] industry ranges from $107.89B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whileOLMA’s FA Score has 1 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • OLMA’s FA Score: 1 green, 4 red.
According to our system of comparison, both NUVL and OLMA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 3 TA indicator(s) are bullish while OLMA’s TA Score has 4 bullish TA indicator(s).

  • NUVL’s TA Score: 3 bullish, 6 bearish.
  • OLMA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, OLMA is a better buy in the short-term than NUVL.

Price Growth

NUVL (@Biotechnology) experienced а -12.96% price change this week, while OLMA (@Biotechnology) price change was -21.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.54%. For the same industry, the average monthly price growth was -1.96%, and the average quarterly price growth was +3.26%.

Reported Earning Dates

NUVL is expected to report earnings on Aug 06, 2026.

OLMA is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Biotechnology (-1.54% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($7.35B) has a higher market cap than OLMA($934M). NUVL YTD gains are higher at: -9.186 vs. OLMA (-57.240). OLMA has higher annual earnings (EBITDA): -164.96M vs. NUVL (-438.9M). NUVL has more cash in the bank: 1.29B vs. OLMA (329M). NUVL (0) and OLMA (0) have equivalent revenues.
NUVLOLMANUVL / OLMA
Capitalization7.35B934M787%
EBITDA-438.9M-164.96M266%
Gain YTD-9.186-57.24016%
P/E RatioN/AN/A-
Revenue00-
Total Cash1.29B329M391%
Total DebtN/A4.48M-
TECHNICAL ANALYSIS
Technical Analysis
NUVLOLMA
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 14 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
NUVL
Daily Signal:
Gain/Loss:
OLMA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DRDBU10.58N/A
N/A
Roman DBDR Acquisition Corp. II
FRO34.68-0.17
-0.49%
Frontline Plc
CV6.86-0.04
-0.58%
CapsoVision
STRR11.59-0.11
-0.98%
Star Equity Holdings Inc
TILE28.79-0.47
-1.61%
Interface

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with PCVX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then PCVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
-1.78%
PCVX - NUVL
51%
Loosely correlated
-3.05%
XNCR - NUVL
50%
Loosely correlated
-5.00%
MLTX - NUVL
49%
Loosely correlated
-5.10%
ZYME - NUVL
49%
Loosely correlated
-1.75%
IDYA - NUVL
48%
Loosely correlated
-3.70%
More

OLMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, OLMA has been loosely correlated with ARVN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if OLMA jumps, then ARVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OLMA
1D Price
Change %
OLMA100%
-15.89%
ARVN - OLMA
41%
Loosely correlated
-6.88%
VERA - OLMA
36%
Loosely correlated
-7.96%
NUVL - OLMA
34%
Loosely correlated
-1.78%
LRMR - OLMA
33%
Poorly correlated
-5.98%
KRYS - OLMA
32%
Poorly correlated
-1.61%
More